A new nasal adrenaline spray, neffy®, has been launched in Canada to provide a needle-free option for emergency treatment of severe allergic reactions, known as anaphylaxis. Approved by Health Canada, this innovative spray is designed for both adults and children weighing over 30 kg. It aims to address a significant concern: nearly half of Canadians surveyed expressed a lack of confidence in using traditional adrenaline auto-injectors during emergencies. With neffy®, users can feel more secure and prepared when facing potentially life-threatening allergies from sources like food, insect stings, or even exercise.

This development is crucial for the estimated 2.5 million Canadians affected by severe allergies. Having an easy-to-carry, needle-free alternative means that people can act quickly in emergencies, which is vital when every second counts. The spray’s design is intended to empower individuals and caregivers to manage allergic reactions more effectively, potentially saving lives in critical situations.

The evidence supporting neffy® comes from its approval process and the ongoing regulatory review of a lower dosage for lighter individuals. While this launch is a positive step, it is essential to remember that the product is still relatively new to the market. As such, users should stay informed about its use and efficacy as more data becomes available. This launch marks a significant milestone in allergy treatment, reflecting a commitment to improving the lives of those living with severe allergies.

Source: ALK’s announcement on the launch of neffy®